These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3133817)

  • 1. Relevance of free tPA assay following venous occlusion in patients with venous thromboembolic disease.
    Alessi MC; Juhan-Vague I; Valadier J; Philip Joet C; Holvoet P; Collen D
    Thromb Haemost; 1988 Apr; 59(2):346-7. PubMed ID: 3133817
    [No Abstract]   [Full Text] [Related]  

  • 2. [Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses].
    Hach-Wunderle V; Scharrer I
    Vasa Suppl; 1993; 39():5-10. PubMed ID: 8322122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome.
    Gandrille S; Jouvin MH; Toulon P; Remy P; Fiessinger JN; Roncato M; Moatti N; Aiach M
    Thromb Haemost; 1988 Jun; 59(3):445-50. PubMed ID: 3142081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis.
    Petäjä J
    Thromb Res; 1989 Oct; 56(2):251-63. PubMed ID: 2515609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery.
    Jansson JH; Norberg B; Nilsson TK
    Clin Chem; 1989 Jul; 35(7):1544-5. PubMed ID: 2503263
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.
    Korninger C; Wagner O; Binder BR
    J Lab Clin Med; 1985 Jun; 105(6):718-24. PubMed ID: 3923146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fibrinolytic therapy--plasminogen activator inhibitors].
    Hönigl K; Pilger E; Stark G; Bertuch H
    Vasa Suppl; 1988; 26():103-6. PubMed ID: 3144048
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of venous occlusion on fibrinolytic potential and plasma storage at -20 degrees C or -70 degrees C.
    Monte G; Melissari E; Kakkar VV
    Recenti Prog Med; 1993 Jun; 84(6):435-7. PubMed ID: 8516552
    [No Abstract]   [Full Text] [Related]  

  • 11. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
    Páramo JA; Alfaro MJ; Rocha E
    Thromb Haemost; 1985 Oct; 54(3):713-6. PubMed ID: 3937269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Poor fibrinolytic response to venous occlusion: defect of endothelial cells or plasma interference?].
    Stalder M; Hauert J; Bachmann F
    Schweiz Med Wochenschr; 1983 Oct; 113(40):1462-4. PubMed ID: 6606226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered fibrinolysis in DVT: influence of site of sampling.
    Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M
    Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial clustering of defective release of t-PA.
    Petäjä J; Rasi V; Vahtera E; Myllylä G
    Br J Haematol; 1991 Oct; 79(2):291-5. PubMed ID: 1958488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.
    Paramo JA; de Boer A; Colucci M; Jonker JJ; Collen D
    Thromb Haemost; 1985 Oct; 54(3):725. PubMed ID: 3937271
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrinolytic parameters in patients undergoing total hip replacement: relationship with the development of asymptomatic deep vein thrombosis and diagnostic usefulness of venous occlusion.
    Trotti R; Siragusa S; Rondanelli M; Chezzi L; Citterio A; Melzi d'Eril GV; Piovella F
    Haematologica; 1997; 82(2):178-81. PubMed ID: 9175322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional determination of tPA, PAI and fibrinogen in endotoxin shock of the pig.
    Spannagl M; Hoffman H; Siebeck M; Fritz H; Schramm W
    Prog Clin Biol Res; 1989; 308():395-9. PubMed ID: 2506572
    [No Abstract]   [Full Text] [Related]  

  • 19. Deficient tissue plasminogen activator release and normal tissue plasminogen activator inhibitor in a patient with recurrent deep vein thrombosis.
    Latham B; Kafoy EA; Barrett O; Gonzalez MF
    Am J Med; 1990 Feb; 88(2):199-200. PubMed ID: 2105644
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of the fibrinolytic system in thrombotic disease.
    Wiman B
    Acta Med Scand Suppl; 1987; 715():169-71. PubMed ID: 3109214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.